Effect of bFGF Peptide Antagonist on Mouse Model Breast Tumor through ERK/MAPK and PI3K/AKT Signaling Pathways

سال انتشار: 1397
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 500

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

ICBCMED14_060

تاریخ نمایه سازی: 21 مرداد 1398

چکیده مقاله:

Introduction & Aim: In the majority of cancers, metastasis of tumor cells is the main cause of treatment failure. Although, surgery and radiotherapy are used effectively in treating local tumor, they are not effective in dealing with metastatic cancers. In such cases, the treatment is often based on chemotherapy. Due to lower side effects of peptide therapy than chemotherapy, it is now a widely used treatment in the world. Therefore, this study intended to investigate the effectiveness of basic fibroblast growth factor (bFGF) peptide designed to inhibit tumor growth in 4T1 metastatic breast cancer through the PI3K/AKT and ERK/MAPK signal transduction pathways.Methods: In BALB/c mice, the tumor was induced through 4T1 tumor graft. When the tumor size was desirable, the treatment was initiated with the bFGF peptide. The designed peptides were injected intraperitoneally at three selected doses for 14 days. The PBS and doxorubicin were injected to the negative and positive control groups, respectively. Tumor size was measured every other day .After the treatment period, the mice underwent a surgery and tumors were used for the western blot examinations. Results: Based on the one-way ANOVA and p≤0.05, it was found that the peptide injection was effective in reducing or inhibiting tumor growth. Results showed that the P-AKT and p-ERK levels in tumors treated with peptide reduced in two mentioned signaling pathways. Conclusion: Findings showed that in the two signal transduction pathways, the P-AKT and p-ERK levels were significantly different from the negative control group.

کلیدواژه ها:

نویسندگان

Mehrzad Jafarzadeh

Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran

Shahrzad Ghadiryan

Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Mohsen Asghari

Department of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran

Mohammad Taghi Joghataei

Department of Neuroscience, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran